Elevated Preoperative Serum CA125 Predicts Larger Tumor Diameter in Patients with Hepatocellular Carcinoma and Low AFP Levels
Table 1
Baseline characteristics of the entire patients (n = 427).
Characteristics
No. of patients
Proportion (%)
Age (years), mean ± SD
56.7 ± 9.5
Gender
Male
366
85.7
Female
61
14.3
Cirrhosis
Yes
366
85.7
No
61
14.3
Virus hepatitis
HBV
359
84.1
HCV
8
1.9
Non-HBC, non-HCV
60
14.0
Antiviral treatment
Yes
359
84.1
No
68
15.9
Child-Pugh
A
415
97.2
B
12
2.8
ALT (U/L), median (IQR)
36.0 (25.0–51.0)
T-Bil (umol/L), median (IQR)
14.8 (11.2–19.4)
Anatomical resection
Yes
146
34.2
No
281
65.8
Surgical margin (mm)
≤10
364
85.2
>10
63
14.8
MTD (cm)
≤5
320
74.9
>5
107
25.1
Number of nodules
1
363
85.0
>1
64
15.0
Microvascular invasion
Yes
91
21.1
No
336
78.7
Differentiation
Well
50
11.7
Mod, poor
377
88.3
TNM stage
I
328
76.8
II
60
14.1
III
39
9.1
HBV, viral hepatitis B; HCV, viral hepatitis C; ALT, alanine transaminase; T-Bil, total bilirubin; MTD, maximal tumor diameter; IQR, interquartile range. In this study, out of a total of 427 patients, 359 were HBV-related HCC patients. They were all treated with nucleic acid analog for hepatitis B. TNM stages were assigned according to the criteria described in the AJCC Cancer Staging Manual (8th Edition).
